Mast cells are permissive for rhinovirus replication: potential implications for asthma exacerbations

Clinical and Experimental Allergy

Volumn 47, Issue 3, 2017, Pages 351-360

  Akoto, C ^a   Davies, D E ^a,b   Swindle, E J ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

asthma; innate immunity; interferon; mast cells; virus

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; INTERFERON REGULATORY FACTOR 7; MESSENGER RNA; MX1 PROTEIN; OAS1 PROTEIN; PROTEIN; RANTES; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; ASTHMA; BRONCHUS EPITHELIUM; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INNATE IMMUNITY; MAST CELL; MAST CELL DEGRANULATION; PRIORITY JOURNAL; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHINOVIRUS INFECTION; UPREGULATION; VIRION; VIRUS PARTICLE; VIRUS RELEASE; VIRUS REPLICATION; VIRUS SHEDDING; CELL LINE; COMMON COLD; COMPLICATION; DRUG EFFECTS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; RHINOVIRUS; SEVERITY OF ILLNESS INDEX; VIROLOGY;

ASTHMA; CELL LINE; COMMON COLD; DISEASE PROGRESSION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INTERFERON-BETA; MAST CELLS; RHINOVIRUS; SEVERITY OF ILLNESS INDEX; VIRUS RELEASE; VIRUS REPLICATION;

EID: 85014117820     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12879     Document Type: Article

References (59)

1. The global asthma report 2014 Auckland, New Zealand: Global Asthma Network; 2014. Available from: http://www.globalasthmanetwork.org/publications/Global_Asthma_Report_2014.pdf
2. 2015 gina report: Global Strategy for Asthma Management and Prevention (GINA); 2015. Available from: http://ginasthma.org/gina-report-global-strategy-for-asthma-management-and-prevention/
3. Jackson DJ, Gangnon RE, Evans MD et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 2008; 178:667–72.
4. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. Br Med J 1993; 307:982–6.
5. Johnston SL, Pattemore PK, Sanderson G et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. Br Med J 1995; 310:1225–9.
6. Bochkov YA, Gern JE. Rhinoviruses and their receptors: implications for allergic disease. Curr Allergy Asthma Rep 2016; 16:30.
7. Hofer F, Gruenberger M, Kowalski H et al. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc Natl Acad Sci USA 1994; 91:1839–42.
8. Bochkov YA, Watters K, Ashraf S et al. Cadherin-related family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus c binding and replication. Proc Natl Acad Sci USA 2015; 112:5485–90.
9. Kelly JT, Busse WW. Host immune responses to rhinovirus: mechanisms in asthma. J Allergy Clin Immunol 2008; 122:671–82.
10. Gern JE, Dick EC, Lee WM et al. Rhinovirus enters but does not replicate inside monocytes and airway macrophages. J Immunol 1996; 156:621–7.
11. Laza-Stanca V, Stanciu LA, Message SD, Edwards MR, Gern JE, Johnston SL. Rhinovirus replication in human macrophages induces nf-κb-dependent tumor necrosis factor alpha production. J Virol 2006; 80:8248–58.
12. Schrauf C, Kirchberger S, Majdic O et al. The ssrna genome of human rhinovirus induces a type i ifn response but fails to induce maturation in human monocyte-derived dendritic cells. J Immunol 2009; 183:4440–8.
13. Vareille M, Kieninger E, Edwards MR, Regamey N. The airway epithelium: soldier in the fight against respiratory viruses. Clin Microbiol Rev 2011; 24:210–29.
14. Jacobs SE, Lamson DM, George KS, Walsh TJ. Human rhinoviruses. Clin Microbiol Rev 2013; 26:135–62.
15. Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunol Rev 2013; 255:25–39.
16. Wark PAB, Johnston SL, Bucchieri F et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005; 201:937–47.
17. Contoli M, Message SD, Laza-Stanca V et al. Role of deficient type iii interferon-lambda production in asthma exacerbations. Nat Med 2006; 12:1023–6.
18. Rupani H, Martinez-Nunez RT, Dennison P et al. Toll-like receptor 7 is reduced in severe asthma and linked to an altered microRNA profile. Am J Respir Crit Care Med 2016; 194:26–37.
19. Sykes A, Macintyre J, Edwards MR et al. Rhinovirus-induced interferon production is not deficient in well controlled asthma. Thorax 2014; 69:240–6.
20. Edwards MR, Regamey N, Vareille M et al. Impaired innate interferon induction in severe therapy resistant atopic asthmatic children. Mucosal Immunol 2012; 6:797–806.
21. Bradding P, Arthur G. Mast cells in asthma - state of the art. Clin Exp Allergy 2016; 46:194–263.
22. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77:1033–79.
23. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346:1699–705.
24. Carroll N, Mutavdzic S, James A. Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax 2002; 57:677–82.
25. Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006; 117:1277–84.
26. Andersson CK, Bergqvist A, Mori M, Mauad T, Bjermer L, Erjefält JS. Mast cell–associated alveolar inflammation in patients with atopic uncontrolled asthma. J Allergy Clin Immunol 2011; 127:905–12.e7.
27. Dougherty RH, Sidhu SS, Raman K et al. Accumulation of intraepithelial mast cells with a unique protease phenotype in t(h)2-high asthma. J Allergy Clin Immunol 2010; 125:1046–53 e8.
28. Balzar S, Fajt ML, Comhair SA et al. Mast cell phenotype, location, and activation in severe asthma. Data from the severe asthma research program. Am J Respir Crit Care Med 2011; 183:299–309.
29. Hinks TSC, Zhou X, Staples KJ et al. Innate and adaptive t cells in asthmatic patients: relationship to severity and disease mechanisms. J Allergy Clin Immunol 2015; 136:323–33.
30. Zhu J, Message SD, Qiu Y et al. Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma. Chest 2014; 145:1219–29.
31. Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol 2004; 4:787–99.
32. Chan CY, St. John AL, Abraham SN. Plasticity in mast cell responses during bacterial infections. Curr Opin Microbiol 2012; 15:78–84.
33. Burke SM, Issekutz TB, Mohan K, Lee PWK, Shmulevitz M, Marshall JS. Human mast cell activation with virus-associated stimuli leads to the selective chemotaxis of natural killer cells by a cxcl8-dependent mechanism. Blood 2008; 111:5467–76.
34. McAlpine SM, Issekutz TB, Marshall JS. Virus stimulation of human mast cells results in the recruitment of cd56+ t cells by a mechanism dependent on ccr5 ligands. FASEB J 2012; 26:1280–9.
35. Brown MG, McAlpine SM, Huang YY et al. Rna sensors enable human mast cell anti-viral chemokine production and ifn-mediated protection in response to antibody-enhanced dengue virus infection. PLoS ONE 2012; 7:e34055.
36. Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD. Activation of mast cells by double-stranded rna: evidence for activation through toll-like receptor 3. J Allergy Clin Immunol 2004; 114:174–82.
37. Lappalainen J, Rintahaka J, Kovanen PT, Matikainen S, Eklund KK. Intracellular rna recognition pathway activates strong anti-viral response in human mast cells. Clin Exp Immunol 2013; 172:121–8.
38. Al-Afif A, Alyazidi R, Oldford SA et al. Respiratory syncytial virus infection of primary human mast cells induces the selective production of type I interferons, cxcl10, and ccl4. J Allergy Clin Immunol 2015; 136:1346–54.
39. Graham AC, Hilmer KM, Zickovich JM, Obar JJ. Inflammatory response of mast cells during influenza a virus infection is mediated by active infection and rig-i signaling. J Immunol 2013; 190:4676–84.
40. Hosoda M, Yamaya M, Suzuki T et al. Effects of rhinovirus infection on histamine and cytokine production by cell lines from human mast cells and basophils. J Immunol 2002; 169:1482–91.
41. Djukanović R, Harrison T, Johnston SL et al. The effect of inhaled ifn-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med 2014; 190:145–54.
42. Kirshenbaum AS, Akin C, Wu Y et al. Characterization of novel stem cell factor responsive human mast cell lines lad 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of fcεri or fcγri. Leuk Res 2003; 27:677–82.
43. Cozens AL, Yezzi MJ, Kunzelmann K et al. Cftr expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol 1994; 10:38–47.
44. Papi A, Johnston SL. Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (icam-1) via increased nf-κb-mediated transcription. J Biol Chem 1999; 274:9707–20.
45. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010; 30:555–64.
46. Marcet C, St. Laurent C, Moon T, Singh N, Befus AD. Limited replication of influenza a virus in human mast cells. Immunol Res 2013; 56:32–43.
47. Brown MG, King CA, Sherren C, Marshall JS, Anderson R. A dominant role for fcγrii in antibody-enhanced dengue virus infection of human mast cells and associated ccl5 release. J Leukoc Biol 2006; 80:1242–50.
48. Bird SW, Maynard ND, Covert MW, Kirkegaard K. Nonlytic viral spread enhanced by autophagy components. Proc Natl Acad Sci USA 2014; 111:13081–6.
49. Bird SW, Kirkegaard K. Escape of non-enveloped virus from intact cells. Virology 2015; 479–480:444–9.
50. Jackson WT, Giddings TH Jr, Taylor MP et al. Subversion of cellular autophagosomal machinery by rna viruses. PLoS Biol 2005; 3:e156.
51. Malmstrom K, Pelkonen AS, Malmberg LP et al. Lung function, airway remodelling and inflammation in symptomatic infants: outcome at 3 years. Thorax 2011; 66:157–62.
52. Okabayashi T, Kojima T, Masaki T et al. Type-iii interferon, not type-i, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res 2011; 160:360–6.
53. Odendall C, Dixit E, Stavru F et al. Diverse intracellular pathogens activate type iii interferon expression from peroxisomes. Nat Immunol 2014; 15:717–26.
54. Sommereyns C, Paul S, Staeheli P, Michiels T. Ifn-lambda (ifn-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4:e1000017.
55. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783–801.
56. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. Double-stranded rna is produced by positive-strand rna viruses and DNA viruses but not in detectable amounts by negative-strand rna viruses. J Virol 2006; 80:5059–64.
57. King CA, Anderson R, Marshall JS. Dengue virus selectively induces human mast cell chemokine production. J Virol 2002; 76:8408–19.
58. St. John AL, Rathore APS, Yap H et al. Immune surveillance by mast cells during dengue infection promotes natural killer (nk) and nkt-cell recruitment and viral clearance. Proc Natl Acad Sci USA 2011; 108:9190–5.
59. Cakebread JA, Xu Y, Grainge C et al. Exogenous ifn-β has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus. J Allergy Clin Immunol 2011; 127:1148–54 e9.